Tecentriq passes neoadjuvant breast cancer trial as Roche looks for early start on the next big checkpoint opportunity
Shot through hundreds of trials over the last decade, checkpoint inhibitors have proven a versatile tool. First approved for melanoma, collectively they now cover dozens of cancer types and settings, earning their developers billions in the process.
Largely, though, they have avoided use in one of the most common settings: Localized tumors typically treated with adjuvant or neo-adjuvant therapy. For drug companies, Cowen estimated last October, it’s a potential $110 billion market, one they’re rapidly trying to fill. The firm noted a long list of trials were underway and due to start reading out — for breast cancer at least — this September with a Roche study in neoadjuvant-stage triple-negative breast cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.